Publications des scientifiques de l'IRD

Aron-Wisnewsky J., Sokolovska N., Liu Y. J., Comaneshter D. S., Vinker S., Pecht T., Poitou C., Oppert J. M., Bouillot J. L., Genser L., Dicker D., Zucker Jean-Daniel, Rudich A., Clement K. (2017). The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia, 60 (10), p. 1892-1902. ISSN 0012-186X.

Titre du document
The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass
Année de publication
2017
Type de document
Article référencé dans le Web of Science WOS:000408770300006
Auteurs
Aron-Wisnewsky J., Sokolovska N., Liu Y. J., Comaneshter D. S., Vinker S., Pecht T., Poitou C., Oppert J. M., Bouillot J. L., Genser L., Dicker D., Zucker Jean-Daniel, Rudich A., Clement K.
Source
Diabetologia, 2017, 60 (10), p. 1892-1902 ISSN 0012-186X
Aims/hypothesis Not all people with type 2 diabetes who undergo bariatric surgery achieve diabetes remission. Thus it is critical to develop methods for predicting outcomes that are applicable for clinical practice. The DiaRem score is relevant for predicting diabetes remission post-Roux-en-Y gastric bypass (RYGB), but it is not accurate for all individuals across the entire spectrum of scores. We aimed to develop an improved scoring system for predicting diabetes remission following RYGB (the Advanced-DiaRem [Ad-DiaRem]). Methods We used a retrospective French cohort (n = 1866) that included 352 individuals with type 2 diabetes followed for 1 year post-RYGB. We developed the Ad-DiaRemin a test cohort (n = 213) and examined its accuracy in independent cohorts from France (n = 134) and Israel (n = 99). Results Adding two clinical variables (diabetes duration and number of glucose-lowering agents) to the original DiaRem and modifying the penalties for each category led to improved predictive performance for Ad-DiaRem. Ad-DiaRem displayed improved area under the receiver operating characteristic curve and predictive accuracy compared with DiaRem (0.911 vs 0.856 and 0.841 vs 0.789, respectively; p = 0.03); thus correcting classification for 8% of those initially misclassified with DiaRem. With Ad-DiaRem, there were also fewer misclassifications of individuals with mid-range scores. This improved predictive performance was confirmed in independent cohorts. Conclusions/interpretation We propose the Ad-DiaRem, which includes two additional clinical variables, as an optimised tool with improved accuracy to predict diabetes remission 1 year post-RYGB. This tool might be helpful for personalised management of individuals with diabetes when considering bariatric surgery in routine care, ultimately contributing to precision medicine.
Plan de classement
Santé : généralités [050] ; Nutrition, alimentation [054]
Description Géographique
FRANCE
Localisation
Fonds IRD [F B010070956]
Identifiant IRD
fdi:010070956
Contact